Zobrazeno 1 - 10
of 118
pro vyhledávání: '"Michelle A. Mahoney"'
Autor:
Steven R. Alberts, Daniel J. Sargent, Garth D. Nelson, Richard M. Goldberg, Stephen N. Thibodeau, Thomas C. Smyrk, Harry H. Yoon, Michelle R. Mahoney, Frank A. Sinicrope
Purpose: To determine the frequency and prognostic association of molecular markers by anatomic tumor site in patients with stage III colon carcinomas.Experimental Design: In a randomized trial of adjuvant FOLFOX ± cetuximab, BRAFV600E and KRAS (exo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3723405e4e923dcadabc0af10aaaaf7b
https://doi.org/10.1158/1078-0432.c.6524849.v1
https://doi.org/10.1158/1078-0432.c.6524849.v1
Autor:
Steven R. Alberts, Daniel J. Sargent, Garth D. Nelson, Richard M. Goldberg, Stephen N. Thibodeau, Thomas C. Smyrk, Harry H. Yoon, Michelle R. Mahoney, Frank A. Sinicrope
Supplemental Table 1. Univariate Cox Proportional Hazards Regression Models for Clinical Factors and Biomarkers (TTR, DFS, and OS)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0cf3021cadf1006b5b68776493f7cd72
https://doi.org/10.1158/1078-0432.22461659
https://doi.org/10.1158/1078-0432.22461659
Autor:
Frank A. Sinicrope, Daniel J. Sargent, Richard M. Goldberg, Stephen N. Thibodeau, Suresh G. Nair, Garth D. Nelson, Michelle R. Mahoney, Steven R. Alberts, Qian Shi, David Tougeron, Harry H. Yoon
Purpose: We examined the prognostic impact of specific KRAS mutations in patients with stage III colon adenocarcinoma receiving adjuvant FOLFOX alone or combined with cetuximab in a phase III trial (N0147). Analysis was restricted to BRAF–wild-type
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9208296a8956c4578543ede96ba27a60
https://doi.org/10.1158/1078-0432.c.6522842
https://doi.org/10.1158/1078-0432.c.6522842
Autor:
Frank A. Sinicrope, Daniel J. Sargent, Richard M. Goldberg, Stephen N. Thibodeau, Suresh G. Nair, Garth D. Nelson, Michelle R. Mahoney, Steven R. Alberts, Qian Shi, David Tougeron, Harry H. Yoon
PDF file - 108KB, Predictive value of specific KRAS mutations in patients with BRAF-wild type resected stage III colon cancer treated with adjuvant FOLFOX chemotherapy with vs without cetuximab. Unadjusted hazard ratios (HR) for disease-free survival
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::76b4763c88758e8f9e5682efd0996687
https://doi.org/10.1158/1078-0432.22454813.v1
https://doi.org/10.1158/1078-0432.22454813.v1
Autor:
Frank A. Sinicrope, Daniel J. Sargent, Richard M. Goldberg, Stephen N. Thibodeau, Suresh G. Nair, Garth D. Nelson, Michelle R. Mahoney, Steven R. Alberts, Qian Shi, David Tougeron, Harry H. Yoon
PDF file - 81KB, Table S1. Multivariable logistic regression models showing the association of clinicopathologic and molecular characteristics with KRAS codon 12 or 13 mutation status in 2,478 BRAF-wild type stage III colon cancers.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ee6b4b974c62a8abe876a46c3ed89ef
https://doi.org/10.1158/1078-0432.22454807.v1
https://doi.org/10.1158/1078-0432.22454807.v1
Autor:
Blake T. Langlais, Mrinal M. Gounder, Ethan Basch, M. Petersen, Gary K. Schwartz, Narre Heon, Michelle R. Mahoney, Alexander J. Zoroufy, Amylou C. Dueck, Lauren J. Rogak, Gita Thanarajasingam, Brenda Ginos, Gina L. Mazza
Publikováno v:
Quality of Life Research. 31:1069-1080
Purpose Missing scores complicate analysis of the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) because patients with and without missing scores may systematically differ. We focus on optimal anal
Autor:
Gina L, Mazza, Molly M, Petersen, Brenda, Ginos, Blake T, Langlais, Narre, Heon, Mrinal M, Gounder, Michelle R, Mahoney, Alexander J, Zoroufy, Gary K, Schwartz, Lauren J, Rogak, Gita, Thanarajasingam, Ethan, Basch, Amylou C, Dueck
Publikováno v:
Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation. 31(4)
Missing scores complicate analysis of the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) because patients with and without missing scores may systematically differ. We focus on optimal analysis met
Autor:
Aminah Jatoi, Shauna Hillman, Peter F. Thall, Elizabeth Storrick, Sumithra J. Mandrekar, Michelle R. Mahoney, Jennifer Le-Rademacher
Publikováno v:
Cancers, Vol 12, Iss 3251, p 3251 (2020)
Cancers
Cancers; Volume 12; Issue 11; Pages: 3251
Cancers
Cancers; Volume 12; Issue 11; Pages: 3251
Simple Summary In cancer clinical trials, adverse event data are collected after every treatment cycle, using the Common Terminology Criteria for adverse events, which includes 837 terms. The vast number of potentially reportable adverse events over
Autor:
Axel Grothey, Jeffrey A. Meyerhardt, Joleen M. Hubbard, Michelle R. Mahoney, Daniel J. Sargent, Nadine Jackson McCleary, Alan P. Venook
Publikováno v:
Journal of Geriatric Oncology. 9:24-31
Objectives While the risk of developing colorectal cancer increases with age, there are limited prospective data regarding best treatment in the older adult population. We launched a phase III trial to evaluate difference in treatment outcome for old
Autor:
Gina L. Mazza, Molly M. Petersen, Brenda Ginos, Blake T. Langlais, Narre Heon, Mrinal M. Gounder, Michelle R. Mahoney, Alexander J. Zoroufy, Gary K. Schwartz, Lauren J. Rogak, Gita Thanarajasingam, Ethan Basch, Amylou C. Dueck
Publikováno v:
Quality of Life Research. 31:1081-1081